

# Per Lundkvist

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2609296/per-lundkvist-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9  
papers

330  
citations

7  
h-index

10  
g-index

10  
ext. papers

417  
ext. citations

5.2  
avg, IF

3.19  
L-index

#	Paper	IF	Citations
9	Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2601-2613	5.6	14
8	Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 193-201	5.6	21
7	FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes. <i>Endocrine</i> , <b>2018</b> , 62, 116-128	4	32
6	Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover. <i>Adipocyte</i> , <b>2018</b> , 7, 285-296	3.2	1
5	A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1511-1532	3.6	9
4	Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. <i>Diabetologia</i> , <b>2018</b> , 61, 1923-1934	10.3	160
3	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1276-1288	6.7	37
2	Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 49-60	6.7	52
1	Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers. <i>Upsala Journal of Medical Sciences</i> , <b>2017</b> , 122, 234-242	2.8	4